Study of Nitazoxanide in the Treatment of Amebiasis in Children
Phase 3
Completed
- Conditions
- Amebiasis
- Registration Number
- NCT00366730
- Lead Sponsor
- Romark Laboratories L.C.
- Brief Summary
The purpose of this study is to determine the effect of nitazoxanide suspension in treating diarrhea caused by Entamoeba histolytica in children.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Age 1 to 11 years.
- Patients with diarrhea (≥3 bowel movements/day) with one or more enteric symptoms such as bloody stools, rectal bleeding or enlarged colon.
- Positive stool ELISA test for Entamoeba histolytica within 7 days prior to enrollment.
Exclusion Criteria
- Patients with identified causes of diarrhea other than E. histolytica.
- Use within 2 weeks of enrollment of any drug or therapy with possible anti-protozoal activity.
- Females who are pregnant, suspected of being pregnant or breastfeeding.
- Serious systemic disorders incompatible with the study.
- History of hypersensitivity to nitazoxanide.
- Patients in whom the possibility of receiving placebo and not being able to receive immediately an effective treatment will be incompatible with the severity of the patient's illness.
- Patients with amebic liver abscess.
- Patients known to have or suspected of having AIDS.
- Patient with immune deficiencies.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Resolution of clinical symptoms of amebiasis
- Secondary Outcome Measures
Name Time Method Eradication of cyst or trophozoites of E. histolytica from post-treatment stool samples Time from initiation of treatment to passage of last unformed stool
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the efficacy of nitazoxanide compared to metronidazole in treating pediatric amebiasis?
What are the molecular mechanisms by which nitazoxanide inhibits Entamoeba histolytica growth?
What biomarkers correlate with treatment response to nitazoxanide in NCT00366730 pediatric amebiasis trial?
What are the most common adverse events associated with nitazoxanide suspension in children?
What combination therapies are being explored for amebiasis alongside nitazoxanide by Romark Laboratories?
Trial Locations
- Locations (2)
University Hospital
🇪🇬Alexandria, Egypt
Benha University Hospital
🇪🇬Benha, Egypt
University Hospital🇪🇬Alexandria, Egypt